Analyst Cuts Freeline Therapeutics' Price Target As Gaucher Program Takes Center Stage, Fabry Program Exits

Freeline Therapeutics Holdings plc FRLN reported 4Q22 and full-year 2022 earnings results on Tuesday.
The company announced strategic priorities and decided to pause the development of FLT190 in Fabry disease to focus its resources on advancing FLT201 Gaucher disease type 1, as well as proposed to reduce its workforce by nearly 30%.
HC Wainwright noted that during the earnings call, management emphasized the significant unmet need for Gaucher disease and the appreciation of gene therapies as critical factors in determining its new strategic focus on developing FLT201.
Also Read: Freeline Therapeutics Stops Further Development On Hemophilia Program, Cuts Workforce.
The analyst removed FLT190 hence cutting the price target from $15 to $2/share and maintaining the Buy rating given the significant potential upside to the new price target from current levels.
Freeline expects to report initial data from GALILEO-1 from the first cohort in 3Q23, which the analyst says could provide initial clinical validation to the program, a key de-risking event.
Price Action: FRLN shares are down 0.05% at $0.44 on the last check Wednesday.